RESEARCH

Identification of two microRNA signatures in whole blood as novel biomarkers for diagnosis of nasopharyngeal carcinoma

Wen Wen1,2†, Shi-Juan Mai1†, Huan-Xin Lin1,2†, Mei-Yin Zhang1, Jia-Ling Huang3, Xin Hua1,2, Chao Lin1,4, Zhi-Qing Long1,2, Zi-Jian Lu1,4, Xiao-Qing Sun1,5, Sai-Lan Liu1,4, Qi Yang1,2, Qian Zhu1, Hui-Yun Wang1 and Ling Guo1,4*

Abstract

Background: Early diagnosis is critical to reduce the mortality caused by nasopharyngeal carcinoma (NPC). Micro-RNAs (miRNAs) are dysregulated and play important roles in carcinogenesis. Therefore, this study aimed to identify diagnostically relevant circulating miRNA signatures in patients with NPC.

Methods: Total RNA was extracted from whole blood samples obtained from 120 patients with NPC, 30 patients with head-neck tumors (HNT), and 30 healthy subjects (HSs), and examined by using a custom microarray. The expression levels of four miRNAs identified by using the microarray were validated with quantitative real-time reverse transcription polymerase chain reaction. The 120 patients with NPC and 30 HSs were randomly assigned to training group-1 and validation group-1, respectively. By using significance analysis of microarray (SAM), the specific miRNA expression profiles in whole blood from patients with NPC are obtained. By using lasso regression and adaptive boosting, a diagnostic signature was identified in training group-1, and its accuracy was verified in validation group-1. By using the same methods, another signature to distinguish patients with NPC from those with HNT and HSs was identified in training group-2 and confirmed in validation group-2.

Results: There were 117 differentially expressed miRNAs (upregulated and downregulated fold change ≥ 1.5) between the patients with NPC and HSs, among which an 8-miRNA signature was identified with 96.43% sensitivity and 100% specificity [area under the curve (AUC) = 0.995] to diagnose NPC in training group-1 and 86.11% sensitivity and 88.89% specificity (AUC = 0.941) in validation group-1. Compared with traditional Epstein–Barr virus (EBV) sero-markers, this signature was more specific for NPC. Furthermore, a 16-miRNA signature to differentiate NPC from HNT and HS (HNT-HS) was established from 164 differentially expressed miRNAs, which diagnosed NPC and HNT-HS with 100% accuracy (AUC = 1.000) in training group-2 and 87.04% (AUC = 0.924) in validation group-2.

Conclusions: The present study identified two miRNA signatures for the highly accurate diagnosis and differential diagnosis of patients with NPC from HSs and patients with HNT. The identified miRNAs might represent novel sero-logical biomarkers and potential therapeutic targets for NPC.

Keywords: MicroRNA, Nasopharyngeal carcinoma, Expression profile, Diagnostic signature
Background

According to the global cancer statistics reported by the International Agency for Research on Cancer, over 84,000 new nasopharyngeal carcinoma (NPC) cases are diagnosed per year, of which more than 80% occur in Asia and 5% in Europe [1]. NPC is highly prevalent in southern China and Southeast Asia, with an annual incidence of 15–50 cases per 100,000 population [2]. It is estimated that in 2015, the incidence and mortality of nasopharyngeal cancer in China were 60,600 and 34,100, respectively [3]. The mortality of NPC has decreased in recent decades because of improvements in treatment technology, especially radiotherapy. Recently, Lv et al. analyzed the data of 7713 patients with NPC obtained from the NCI SEER 17 program released in 2015 and revealed that patients had a 5-year overall survival (OS) of 57.4% in 2000–2007 [4], indicating that the 5-year OS is not satisfactory and should be improved. Furthermore, current treatment decisions depend mainly on the tumor-node-metastasis (TNM) staging system. The common consensus is that stage I NPC is treated by radiotherapy alone, stage II disease by radiotherapy with or without concurrent chemotherapy, and stage III to IV(B) by radiochemotherapy [5, 6]. If patients are diagnosed at an early stage, such as stage I, they only need to receive simple radiation treatment and have a very good prognosis, with few adverse reactions to the therapy. This clearly indicates that early diagnosis is critical to improve the survival and life quality of patients with NPC. Clinically, however, as NPC is asymptomatic or has non-specific symptoms at the early stage, more than 80% of patients with NPC are first diagnosed at a late stage (III or IV), often with cervical lymph node metastasis [7], which leads to reduced survival. Therefore, early diagnosis of NPC is a significant clinical challenge.

Usually, nasopharyngeal biopsy examination and radiological imaging are the most important tools to diagnose NPC, which provide the most definitive evidence to determine the clinical stage, prognosis, and treatment. However, these methods are invasive and painful diagnostic procedures, and are not suitable for early diagnosis or screening NPC in an endemic area. Numerous studies have indicated that the occurrence of NPC is very closely related to Epstein–Barr virus (EBV) infection [8]; therefore, detecting serum anti-EBV antibodies has been used as a non-invasive test to diagnose NPC for more than 40 years [9, 10]. Recently, serum EBV DNA also has been used as a biomarker for NPC diagnosis [11]. However, the etiology and mechanism of how EBV causes this disease are not fully understood [12, 13]. More importantly, the sensitivity and specificity of EBV antibodies are not satisfactory to diagnose NPC. Therefore, other circulating biomarkers have been explored for NPC diagnosis, such as DNA methylation markers [14], fragments of cytohistatin 18 [15], cathepsin B (CTSB) and D (CTSD) [16], insulin-like growth factor 1 (IGF-1) [17], arginase 2 (ARG2) [18], autoantibodies against peroxiredoxin 2 (PRDX2) and PRDX3 [19], and long noncoding RNAs [20]. However, these biomarkers require further confirmation in large prospective studies, and currently, none of them have been used in clinical practice. Therefore, new serum biomarkers for the early diagnosis of NPC are urgently required.

MicroRNAs (miRNAs) are a class of small non-coding RNAs of approximately 21–24 nucleotides in length, which lead to the degradation of target mRNAs and/or repression of their translation by complementary binding to their 3′ untranslated region (UTR) [21, 22]. MiRNAs are implicated in various cancers and function as both oncogenes and tumor suppressors in tumor initiation, progression, and response to treatment [23, 24]. Therefore, there are many reports of the use of miRNAs as biomarkers for diagnosis, prognosis, and treatment of cancers. Furthermore, miRNAs can be released from various tumor tissues into circulation during cancer development and progression, indicating the potential of circulating miRNAs as novel noninvasive diagnostic biomarkers for a variety of cancers [25–30]. miRNAs are also aberrantly expressed in NPC tissues [31–33], and serum or plasma miRNAs could be used as biomarkers to diagnose NPC [34, 35].

Recently, miRNAs extracted from whole blood, including plasma and blood cells, have been reported as biomarkers for the early detection of pancreatic cancer [36–38], ovarian cancer [39], lung cancer [40, 41], and gallbladder cancer [42]. miRNAs from whole blood, including white blood cells (neutrophils, eosinophils, basophils, monocytes, and lymphocytes), can be used as diagnostic biomarkers, based on the theory that these circulating white blood cells, as part of the immune system, monitor the patients’ physiological and pathological state and can respond to them by altering their transcriptome [43]. The advantages of whole blood miRNA samples are as follows: (1) A high miRNA yield [44]; (2) it is less error-prone than serum or plasma samples, and (3) the detected miRNAs may originate from plasma, blood cells, circulating tumor cells, tumor tissues, or various organs. Thus, miRNAs from whole blood yield more comprehensive information than those from serum, plasma, or white blood cells [38, 39]. Furthermore, miRNAs in whole blood can originate from distant inflammatory foci. Thus, they are more sensitive in inflammation-related cancers, such as chronic pancreatitis related pancreatic cancer and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) [38]. NPC is also considered an inflammation-related cancer [45]. Therefore, whole blood miRNAs...
should be a better biomarker than serum or plasma miRNAs to diagnose NPC. To the best of our knowledge, there have been no reports on the diagnostic value of whole blood miRNAs in patients with NPC to date.

Early diagnosis of NPC remains the major issue in clinical practice. In this study, a custom miRNA microarray was employed to profile miRNA levels in whole blood from healthy subjects (HSs), patients with NPC, and those with head-neck tumors (HNT). The study aimed to identify non-invasive miRNA signatures to diagnose NPC and to differentially diagnose NPC and HNT with higher accuracy.

Materials and methods

Patients and blood samples

Whole blood samples were collected from healthy volunteers termed healthy subjects (HS, n = 30), patients with NPC (n = 120), and those with head-neck tumors (HNT) (n = 30) at the Sun Yat-Sen University Cancer Center during May 2015 to March 2017. Healthy subjects were recruited from those participating in annual physical examination for cancer at the cancer center. The patients were pathologically and clinically diagnosed as NPC or HNT, and staged according to the TNM staging system of International Union against Cancer. The characteristics of all subjects are listed in Table 1. The inclusion criteria and exclusion criteria for patients with NPC are shown in Table 2. None of the patients with HNT were subjected to any treatment, such as surgery, radiotherapy, or chemotherapy, before blood sampling. The Ethical Committees of Sun Yat-Sen University Cancer Center approved this study. Written informed consent was obtained from all participants in the study.

RNA extraction

Approximately 2–3 ml of whole blood from each donor was drawn into a Blood RNA Preservative Tube and RNA extraction was performed by using an RNA Purification Kit (Norgen Biotek, Thorold, Ontario, Canada) following the manufacturer’s protocol. Briefly, 1.5 ml of RNA Extraction Buffer A and 1.5 ml of RNA Extraction Buffer B were added to the 3 ml of whole blood and mixed well and incubated at −20 °C for 10 min. Thereafter, the mixture was centrifuged at 4°C at 4000 rpm for 30 min. After discarding the supernatant, 570 μl of Resuspension Solution B and 330 μl of 100% Ethanol were added into the remaining liquid and mixed well. The mixture was then added into a MiniSpin column and the column was centrifuged at 3500 rpm at 4 °C for 1 min. Subsequently, the column was washed three times with 100 μl of Wash Solution A. Finally, 100 μl of Elution Solution A was added into the column and centrifuged at 4 °C at 1000 rpm for 2 min. The RNA concentration was measured by using an ND-1000 spectrophotometer (Nanodrop Technologies).

| Table 1 The clinical characteristics of patients with NPC and controls |
|-------------------------------------------------------------|
| **Clinical characteristics** | NPC (N = 120) | HNT (N = 30) | HS (N = 30) |
| Age (years) | 45.2 | 55.9 | 27.1 |
| Sex ratio | Male | 91 | 24 | 15 |
| Female | 29 | 6 | 15 |
| T stage | 1 | 7 | 13 |
| 2 | 19 | 6 |
| 3 | 67 | 8 |
| 4 | 27 | 3 |
| N stage | 0 | 6 | 20 |
| 1 | 26 | 5 |
| 2 | 66 | 5 |
| 3 | 22 | 0 |
| M stage | 0 | 116 | 30 |
| 1 | 4 | 0 |
| Clinical stage | I | 0 | 12 |
| II | 8 | 5 |
| III | 65 | 9 |
| IV | 47 | 4 |

Microarray detection

The miRNA microarray was designed and fabricated as described previously [46, 47]. Briefly, the microarray, which was fabricated in our laboratory, contains 1849 probes for miRNA species sourced from the miRBase database (Release 18.0). The RNA (1.0–1.5 μg) samples were labeled with 100 nmol/l of pCp-Cy5 (Jena Bioscience, Germany) and 15 units of T4 RNA ligase (USB) in a total 20 μl of reaction volume at 16 °C overnight. Then, equal volumes of labeled RNA sample and 2× hybridization solution were mixed well and hybridized onto the microarray for 12–18 h at 45 °C. After hybridization, the microarrays were washed in 1× SSC/1% SDS for 10 min at 45 °C, followed by sequential washing in 0.5× SSC/0.1% SDS solution twice, 0.2× SSC twice and purified water once for 1 min each time at room temperature. Finally, the microarray was dried in a special small centrifuge and scanned using a LuxScan-10K instrument (CapitalBio, China).
Gene expression data extraction
The microarray scanning images were digitized by using the GenPix Pro 6.0 program, and the original signal data were extracted. After subtracting the background, the averaged signals of replicated probes were normalized using Quantile normalization. The normalized data were then converted into their log2 values. The microarray data have been deposited in the Gene Expression Omnibus of the National Center for Biotechnology Information (GSE118613).

Quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR)
For qRT-PCR, total RNA (10 ng) was reverse transcribed into cDNA by using an All-in-One™ miRNA qRT-PCR Reagent Kit (GeneCopoeia) containing Poly A polymerase, a unique Oligo-dT Adaptor primer, and M-MLV Reverse Transcriptase. The quantitative PCR reactions were then carried out with an All-in-One™ qPCR Mix containing SYBR® Green, first-strand cDNA, specific miRNA primers, and the Universal Adaptor PCR Primer (GeneCopoeia) on a PRISM 7900HT system (Applied Biosystems). Every sample was analyzed in triplicate wells, and reactions excluding cDNA were used as negative controls. The thermal cycling conditions were: 95 °C for 10 min for a hot start, and then 40 cycles at 95 °C for 15 s, 60 °C for 20 s, and 72 °C for 10 s. U48 RNA was employed as the endogenous control. The qRT-PCR data were firstly normalized by U48 expression and then by a mean expression value of a given miRNA in the HSs. Therefore, the relative quantification of miRNA expression was presented as $2^{-\Delta\Delta C_t}$.

Statistical analysis
Student’s t-test and significance analysis of microarray (SAM) were employed to identify the differentially expressed miRNAs (upregulated and downregulated fold change ≥ 1.5, P < 0.001 and false discovery rate (FDR)-q < 0.05) between the NPC subjects and control subjects (HS and HNT). Lasso regression was then used to screen for the significant miRNAs, which were used to build the diagnostic model for NPC by using Adaptive Boosting. Receiver operating characteristic (ROC) analysis was performed to show the diagnostic efficiency of the 8-miRNA signature and the 16-miRNA signature in the R3.4.0 software.

Results
The miRNA expression profiles of whole blood in patients with NPC and those with HNT
As far as we know, there have been no reports on miRNA expression profiles of whole blood in patients with NPC. In the present study, the miRNA profiles of the whole blood in patients with NPC were first investigated. A total of 150 whole blood samples were collected from 120 patients with NPC and 30 HSs, and total RNA was extracted from these samples. miRNA expression was detected with the custom miRNA microarray. By using SAM software and Student’s t-test, 117 differentially expressed miRNAs (upregulated and downregulated fold change ≥ 1.5) were identified between the patients with NPC and HSs with the FDR set to zero. Among these differential miRNAs, 99 were upregulated and 18 were downregulated in the NPC samples. The SAM plot sheet of miRNAs was presented in Fig. 1a.

In clinical practice, NPC should be discriminated from other HNT patients. In this case, the miRNA profiles between patients with NPC and those with HNT plus the HSs (HNT-HS) were explored. Therefore, whole blood samples from 30 patients with HNT were collected to investigate the miRNA expression by using the microarray. By using the same method as described above, 164 miRNAs that were significantly differentially altered between the NPC group and the HNT-HS group were identified, of which 128 were upregulated and 36 were downregulated in the NPC group. The SAM plot sheet of miRNAs was showed in Fig. 1b. Altogether, two miRNA profiles were identified between the NPC group and HS or HNT-HS group, which would provide the clues to develop diagnostic or differential diagnostic markers, prognostic markers, and therapeutic targets in NPC.

To confirm the reliability of the results from the miRNA microarray, the levels of four randomly selected miRNAs (miR-4790-3p, miR-188-5p, miR-5583-5p, and miR-3615) were measured by using qRT-PCR in randomly chosen blood samples of 10 NPCs and 10 HSs. The qRT-PCR
results showed that the levels of miR-4790-3p and miR-188-5p were significantly upregulated in the NPC samples compared with that in the HS samples, and the levels of hsa-miR-5583-5p and hsa-miR-3615 were also higher in NPC samples than in the HS samples but the difference was not significant (Fig. 2). These results were consistent with the results obtained by using the microarray analysis (Fig. 3). This result demonstrated that the data from the miRNA microarray analysis were reliable and could be used for further analysis.

Identification of an 8-miRNA signature to diagnose NPC in the training group-1 and its verification in the validation group-1

This study's main aim was to identify a miRNA signature to diagnose NPC. To this end, a total of 150 whole blood samples (120 from patients with NPC and 30 from HSs) were randomly divided into a training group-1, which included 84 NPC samples and 21 HS ones, and a validation group-1 containing 36 NPC samples and 9 HS ones. To build a diagnostic model for NPC, Lasso regression screened out
eight significant candidate miRNAs in the training group-1 (Table 3). Then, the microarray expression values of the eight miRNAs in the training group-1 were used to build a diagnostic model to calculate the diagnostic scores by using the AdaBoost machine-learning algorithm in the R 3.4.0 program. A linear combination of M base regressors was constructed and the final boosted model was obtained (the detailed process is described in Additional file 1: Method S1):

\[ f(x) = \sum_{i=1}^{M} \alpha_i G_m(x) \]

In this model, M is 1000. The diagnostic score could be obtained by using this boosted model in the R 3.4.0 program.

As shown in Fig. 4a, the eight miRNAs were ranked by their roles in the diagnostic model. If the score was greater than or equal to 0.708, the subject was diagnosed as a patient with NPC; otherwise, the subject is diagnosed as a HS. In this way, the 8-miRNA signature diagnosed NPC with 97.14% accuracy (sensitivity: 96.43%, specificity: 100%) in the training group-1 (Table 4 and Additional file 1: Table S1). The ROC analysis showed that the area under the curve (AUC) of the 8-miRNA signature was 0.995, with a P value less than 0.001 in the training group-1 (Fig. 5a).

To verify the diagnostic value of the 8-miRNA signature identified in the training group-1, the reproducibility of the diagnostic signature was further verified in the validation group-1. The result in the validation group-1 indicated an accuracy of 86.67% (sensitivity: 86.11%, specificity: 88.89%) (Table 5 and Additional file 1: Table S2). The ROC analysis
revealed that the AUC of this signature is 0.941 in the validation group-1 (P < 0.01) (Fig. 5b). The results indicate this 8-miRNA signature is a powerful and reproducible biomarker to diagnose NPC.

Identification and Verification of the 16-miRNA signature to differentiate NPC from other head-neck tumors and healthy subjects in the second training and validation groups

The differential diagnosis of NPC and other head-neck tumors is difficult in some cases; therefore, an miRNA signature was sought that could differentiate NPC from HNT. Whole blood samples from 30 patients with HNT
were collected in the same cancer center. In the clinic, physicians simply need to determine if the patient has NPC or not. Therefore, the 30 patients with HNT were combined with the 30 HSs mentioned above as a control group (the HNT-HS group). The 180 samples (120 NPCs, 30 HNTs, and 30 HSs) were also randomly divided into a training group-2 (including 84 NPCs, 20 HNTs and 22 HSs) and a validation group-2 (containing 36 NPCs, 10 HNTs, and 8 HSs). Lasso regression identified 16 miRNAs from 164 differentially expressed miRNAs for the diagnosis of patients with NPC in comparison with the HNC-HS group (Table 6). Then, the expression values of the 16 miRNAs were used to construct another diagnostic model to compute the diagnostic scores for all subjects by using AdaBoost machine-learning algorithm in the R 3.4.0 software. The rankings of the roles of the 16 miRNAs in this 16-miRNA diagnostic signature are shown in Fig. 4b. With 0.5 as the cutoff value, if the diagnostic score of a subject was larger or equal to 0.5, the subject would be diagnosed as having NPC; otherwise the subject would belong to the HNT-HS group. In this way, this diagnostic model yielded a 100% accuracy rate (100% sensitivity and 100% specificity) in the training group-2 (Table 7 and Additional file 1: Table S3). Similarly, the ROC curve analysis showed that the AUC of the 16-miRNA signature was 1.000 (P < 0.01) (Fig. 5c).

To further determine the diagnostic capacity of this signature, we calculated the diagnostic score for each subject using the expression value of 16 miRNAs in validation group-2 with the 16-miRNA diagnostic signature model established in training group-2. The result showed that the 16-miRNA diagnostic signature model led to 94.44% sensitivity and 72.22% specificity for NPC diagnosis in validation group-2 (Table 8 and Additional file 1: Table S4). At the same time, the ROC analysis showed that the AUC of the 16-miRNA signature was 0.924 (P < 0.01) (Fig. 5d). The results showed that the 16-miRNAs could correctly distinguish the patients with NPC from the HSs and HNT patients.

**Discussion**

With progress in high-throughput examination techniques for miRNAs, an increasing number of circulating miRNAs have been observed to be correlated with tumor diagnosis, progression, prognosis, and treatment response, demonstrating that these miRNAs have a large potential for diagnosis, prognosis, and treatment in patients with tumors [33, 48]. The circulating miRNAs with altered level have been proposed as promising biomarkers with several advantages, including stability in body fluid samples, non-invasive sampling, and easy and rapid manipulation. However, published data about the peripheral blood miRNA profiles in patients with NPC are limited.
Zeng et al. [35] reported that four miRNAs (miR-17, miR-20a, miR-29c, and miR-223) were expressed differentially in the serum of 20 patients with NPC compared with that in 20 non-cancerous controls. Prediction of NPC by using the 4-miRNA-based diagnostic equation with a new Ct difference method gave 97.3% sensitivity and 96.5% specificity. In the study of Zheng et al. [49], miR-548q and miR-483-5p were identified as potential biomarkers of NPC by comparing the plasma miRNA profiles of 31 patients with NPC and 19 controls. The combination of these two miRNAs obtained 67.1% sensitivity and 68.0% specificity for NPC diagnosis. Liu et al. [50] identified that miR-22, miR-572, miR-638, and miR-1234 were differentially altered in the serum of patients with NPC, and the 4-miRNA signature may add prognostic value to the TNM staging system. Wang et al. [51] used next-generation sequencing to verify that the plasma level of miR-483-5p, miR-103,
and nmiR-29a could be helpful to predict survival in patients with NPC.

Previously, we identified a 5-miRNA signature including miR-93, miR-142-3p, miR-29c, miR-26a, and miR-30e as an independent prognostic factor of NPC from 312 paraffin-embedded NPC specimens by using a custom microarray containing 873 miRNA probes in 2012 [32].

The total number of miRNAs has increased substantially in recent years; therefore, 1849 probes for miRNAs were designed according to miRBase database (Release 18.0) and applied in the present study. In this study, 117 differentially expressed miRNAs were found between patients with NPC and HSs, 99 of which were upregulated and 18 were downregulated in patients with NPC in the training group-1. The finding that miRNAs upregulated in whole blood outnumbered those that were downregulated in patients with NPC was consistent with a previous report that miRNA activity is globally increased in cancers [52].

In recent decades, many reports have shown that the development and progression of NPC is a strongly associated with the human herpesvirus, Epstein–Barr virus (EBV). Studies have shown that patients with NPC have high levels of a broad spectrum of EBV antibodies [53–55]. Detection of a combination of IgA antibodies against EBV capsid antigen (VCA/IgA) and early antigen (EA/IgA) by using an immunofluorescence assay has been established as a standard tool for NPC screening [56]. However, the sensitivity and specificity of the combination of two IgA antibodies were 50.9% and 95.2%, respectively, indicating lower sensitivity. This might be reflect the fact that EBV is a member of the herpesvirus family and causes persistent infection in more than 90% of adults [57, 58]. Moreover, EBV infection is involved in other hematological and epithelial malignancies, such as Hodgkin's lymphoma, Burkitt's lymphoma, and gastric carcinoma [8, 53, 59, 60].

In the present study, there was a considerable difference in ages between the patients with cancer and the HSs. Although it may have some impact on miRNA expression levels, we believe that the influence is small and not significant. For example, in the study of Muñoz-Culla et al. in 2017, blood leucocytes of 38 healthy subjects aged from 24 to 79 years old were detected with 847 miRNA probes, and 35 miRNAs showed ≥1.5-fold change [61]. However, only has-miR-1280 in the 16-miRNA signature is one of these 35 miRNAs, indicating that the miRNA level changes related to ages would have a very limited impact on miRNA expression profiling in patients with NPC.

The 8-miRNA signature was identified with a high diagnostic value for distinguishing NPC from HSs (96.43% sensitivity and 100% specificity in the first training group and 86.11% sensitivity and 88.89% specificity in the first validation group). Compared with traditional seromarkers, this 8-miRNA signature has a much higher sensitivity for NPC. During 2006 and 2010, only 4.5% (120/2671) of patients with NPC in the Sun Yat-Sen University Cancer Center had stage I–II disease, suggesting that early diagnosis is a major challenge. In the present study, the proportion of early stage patients (including stage I and II)

### Table 6 Sixteen miRNAs identified by Lasso regression in the Training Group-2

| Variables          | Lasso coefficient |
|--------------------|-------------------|
| (Intercept)        | −5.5820           |
| hsa-miR-1224-3p    | 0.2305            |
| hsa-miR-1280       | −0.0086           |
| hsa-miR-155-5p     | −0.2466           |
| hsa-miR-1908       | 0.0121            |
| hsa-miR-1973       | −0.0849           |
| hsa-miR-296-5p     | 0.1406            |
| hsa-miR-361-3p     | 0.0403            |
| hsa-miR-425-5p     | 0.0401            |
| hsa-miR-4284       | −0.3668           |
| hsa-miR-4438-5p    | −0.2057           |
| hsa-miR-4439       | 0.0300            |
| hsa-miR-4665-3p    | 0.2091            |
| hsa-miR-4706       | 0.1847            |
| hsa-miR-4740-3p    | 0.1901            |
| hsa-miR-5091       | −0.1342           |
| hsa-miR-513b       | 0.5499            |

### Table 7 The diagnostic results of the 16-miRNA signature in the Training Group-2

| Actual diagnosis | The diagnostic results of 16-miRNAs | Total |
|------------------|-------------------------------------|-------|
|                  | NPC N (%)  | HS + HNT N (%) |       |
| NPC              | 84 (100.0) | 0 (0.0)       | 84    |
| HS + HNT         | 0 (0.0)    | 42 (100.0)    | 42    |
| Total            | 84         | 42            | 126   |

### Table 8 The diagnostic results of the 16-miRNA signature in the Validation Group-2

| Actual diagnosis | The diagnostic results of 16-miRNAs | Total |
|------------------|-------------------------------------|-------|
|                  | NPC N (%)  | HS + HNT N (%) |       |
| NPC              | 34 (94.4)  | 2 (5.6)       | 36    |
| HS + HNT         | 5 (27.8)   | 13 (72.2)     | 18    |
| Total            | 39         | 15            | 54    |
In the present study, we profiled miRNA expression levels in the whole blood of patients with NPC and identified two miRNA signatures (8-miRNA and 16-miRNA signatures) with high diagnostic accuracy for NPC, HS, and HNT-HS subjects. The 8-miRNA and 16-miRNA signatures are promising and potentially powerful biomarkers for the diagnosis and differential diagnosis of NPC, and are the first reported diagnostic signatures for NPC identified from whole blood samples. In addition, to the best of our knowledge, the 16-miRNA signature is the first meaningful diagnostic signature to differentiate NPC from head-neck tumors and healthy subjects. Moreover, the role and mechanism of the miRNAs in the two signatures in the development, progression, and immuno-reactivity of NPC should be explored in a future study. Further multicenter prospective studies are warranted to validate these diagnostic signatures for NPC.

Additional file

Additional file 1. Additional Methods and Tables.

Abbreviations
NPC: nasopharyngeal carcinoma; miRNAs: microRNAs; HNT: head-neck tumor; OS: overall survival; TNM: tumor-node-metastasis; EBV: Epstein–Barr virus; SAM: significance analysis of microarray; qRT-PCR: quantitative real-time reverse transcription polymerase chain reaction; HBV: hepatitis B virus; HCC: hepatocellular carcinoma; HS: healthy subject; RPM: revolutions per minute; ROC: receiver operating characteristic; AUC: area under the curve; FDR: false discovery rate.

Acknowledgements
Authors would like to thank the patients and volunteers who participated in this study.

Authors’ contributions
LG and HYW conceived and designed this study; WW and MYZ performed the experiments; XQS, XH, CL, ZQL, and ZJL acquired the data; JLH, WW, QY, and QZ analyzed the data and results; WW, SJM, and HXL wrote the manuscript; and LG and HYW improved and revised the manuscript. All authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China [Grant Numbers 81772877, 81572848, 81773103, 81872459 and 81803050]; the Natural Science Foundation of Guangdong Province [Grant Numbers 2018A030310422]; the Social Science and Technology Development Major Project of Dongguan [Grant Number 20185071050241630]; and the Science and Technology Department of Guangdong Province, China [Grant Number 2017A030310422].

Availability of data and materials
The datasets supporting the conclusions of this article are included within the article (and its additional files).

Consent for publication
Not applicable.

Ethics approval and consent to participate
The study was approved by the Research Ethics Committee of Sun Yat-Sen University Cancer Center. Research conduct conformed to all ethical standards, and written informed consent was obtained from all patients.

Competing interests
The authors declare that they have no competing interests.
Author details
1 State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China. 2 Department of Radiotherapy, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China. 3 Research Unit of Molecular Epidemiology, Helmholtz Zentrum München, Neuherberg, Germany. 4 Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China. 5 Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060, People’s Republic of China.

Received: 17 February 2019  Accepted: 15 May 2019
Published online: 03 June 2019

References
1. Lee AW, Ng WT, Chan YH, Sze H, Chan C, Lam TH. The battle against nasopharyngeal cancer. Radiather Oncol. 2012;104(3):272–8.
2. Zhang L, Chen QY, Liu H, Tang LQ, Mai HQ. Emerging treatment options for nasopharyngeal cancer. Drug Des Dev Ther. 2013;7:37–52.
3. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.
4. Lv JW, Huang XD, Chen YP, Zhou GQ, Tang LL, Mao YP, Li WF, Lin AH, Ma J, Sun Y. A National Study of survival trends and conditional survival in nasopharyngeal carcinoma: analysis of the national population-based surveillance epidemiology and end results registry. Cancer Res Treat. 2018;50(2):324–34.
5. Chan AT, Gregoire V, Lefebvre JL, Licitra L, Hui EP, Leung SF, Felip E. Nasopharyngeal carcinoma: EHNS-ESMO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vi883–5.
6. National Comprehensive Cancer Network. NCCN guidelines for treatment of cancer by site and head and neck cancers. https://www.nccn.org/professionals/physician_gls/default.aspx#site. Accessed 2018.
7. Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM. Two-step Epstein-Barr virus immunoglobulin A enzyme-linked immunosorbent assay system for serological screening and confirmation of nasopharyngeal carcinoma. Clin Vaccine Immunol. 2009;16(5):706–11.
8. Tsao SW, Tsang CM, Lo KW. Epstein-Barr virus infection and nasopharyngeal carcinoma. Philos Trans R Soc Lond Ser B Biol Sci. 2017;372(1732):20160270.
9. Chen Y, Xin X, Cui Z, Zheng Y, Guo J, Chen Y, Lin Y, Su G. Diagnostic value of serum Epstein-Barr virus capsid antigen-IgA for nasopharyngeal carcinoma: a meta-analysis based on 21 studies. Clin Lab. 2016;62(6):1155–66.
10. Pearson GR. Epstein-Barr virus and nasopharyngeal carcinoma. J Cell Biochem Suppl. 1993;17f:150–4.
11. Han BL, Xu XY, Zhang CZ, Wu JJ, Han CF, Wang H, Wang X, Wang GS, Yang Z, et al. Diagnostic value of serum Epstein-Barr virus capsid antigen-IgA for nasopharyngeal carcinoma: a meta-analysis based on 21 studies. Clin Lab. 2016;62(6):1155–66.
12. Pearson GR. Epstein-Barr virus and nasopharyngeal carcinoma. J Cell Biochem Suppl. 1993;17f:150–4.
13. Busson P, Kreyer C, Ostka T, Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol. 2004;12(8):356–60.
14. Jiang W, Cai R, Chen QQ. DNA methylation biomarkers for nasopharyngeal carcinoma: diagnostic and prognostic tools. Asian Pac J Cancer Prev AIPC. 2012;13(6):2577–81.
15. Abdulamirs A, Hafidh RR, Abdulmuhaimen N, Abubakar F, Abbas KA. The distinctive profile of risk factors of nasopharyngeal carcinoma in comparison with other head and neck cancer types. BMC Public Health. 2008;8:400.
16. Sengupta S, den Boon JA, Chen YJ, Chen M, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633–41.
17. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 2010;5(10):e13733.
18. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE. 2010;5(10):e13733.
19. Zhou J, Yu L, Gao X, Hu J, Wang J, Dai Z, Wang JF, Zhang Z, Lu S, Huang X, et al. Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol. 2011;29(36):4781–8.
20. Zuo Z, Calin GA, de Paula HM, Medeiros LJ, Fernandez MH, Shimizu M, Garcia-Manero G, Bueso-Ramos CE. Circulating microRNAs let-7a and mir-16 predict progression-free survival and overall survival in patients with myelodysplastic syndrome. Blood. 2011;118(2):413–5.
21. Chen HC, Chen GH, Chen YH, Liao WL, Liu CY, Chang KP, Chang YS, Chen SJ. MicroRNA deregulation and pathway alterations in nasopharyngeal carcinoma. Br J Cancer. 2009;100(6):1002–11.
22. Liu N, Chen NY, Cui RX, Li WF, Li Y, Wei RR, Zhang MY, Sun Y, Huang BJ, Chen M, et al. Prognostic value of a microRNA signature in nasopharyngeal carcinoma: a microRNA expression analysis. Lancet Oncol. 2012;13(6):633–41.
23. Sengupta S, den Boon JA, Chen IH, Stanhope SA, Cheng YJ, Chen CJ, Hildesheim A, Sugden B, Alhquist P. MicroRNA 29c is down-regulated in nasopharyngeal carcinomas, up-regulating miRNAs encoding extracellular matrix proteins. Proc Natl Acad Sci USA. 2008;105(15):5874–8.
24. Wang Z, Chen W, Zhang Y, Lu Y, Wang Q. Diagnostic value of circulating microRNAs for nasopharyngeal cancer: a systematic review and meta-analysis. J Cancer Res Ther. 2014;10(Suppl):C173–8.
25. Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z, et al. Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS ONE. 2012;7(10):e46367.
26. Bauer AS, Keller A, Costello E, Greenhalf W, Bier M, Borries A, Beier M, Neoptolemos J, Buchler M, Werner J, et al. Diagnosis of pancreatic ductal adenocarcinoma and chronic pancreatitis by measurement of microRNA abundance in blood and tissue. PLoS ONE. 2012;7(4):e34151.
27. Ganeopola GA, Rutledge JR, Suman P, Yengraksawana A, Chang DH. Novel blood-based microRNA biomarker panel for early diagnosis of pancreatic cancer. World J Gastrointest Oncol. 2014;6(1):22–33.
28. Schultz NA, Dehlerdorff C, Jensen BV, Bjergaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holland NH, et al. MicroRNA
51. Wang HY, Yan LX, Shao Q, Fu S, Zhang ZC, Ye W, Zeng YX, Shao JY. Profiling biomarkers in whole blood for detection of pancreatic cancer. JAMA. 2014;311(4):392–404.

52. Israel A, Sharan R, Ruppin E, Galun E. Increased microRNA activity in human cancers. PLoS ONE. 2009;4(6):e6045.

53. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an etiologic driver of tumorigenesis. Can Res. 2012;72(14):3445–50.

54. Tsao SW, Tsang CM, To KF, Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol. 2015;235(2):523–33.

55. Zhang H, Wang J, Yu D, Liu Y, Xue K, Zhao X. Role of Epstein-Barr Virus in the Development of Nasopharyngeal Carcinoma. Open Med (Warsaw, Poland). 2017;12:171–8.

56. Tang B, Liu Q, Cui Y, Hong M, Zhu X, Yue H. Protocols of screening, early detection and diagnosis for nasopharyngeal carcinoma in PR China. Beijing: People’s Medical Publishing House of P.R. China; 2009. p. 187–8.

57. Cohen J. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92.

58. Coghill AE, Hildesheim A. Epstein-Barr virus antibodies and the risk of associated malignancies: review of the literature. Am J Epidemiol. 2014;180(7):687–95.

59. Hooi-Kaas M, Kruise E, Wiertz J, Tjebbe R, Leebink RJ. Comprehensive profiling of micro-RNA biomarkers in blood, plasma, serum and sputum: a review and summary of current literature. Int J Mol Med. 2016(7):494.

60. Li G, Pu Y. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumour Biol. 2015;36(9):6985–90.

61. Patnaik SK, Yendamuri S, Kannisto E, Kucharczuk JC, Singhal S, Vachani A.miRNA expression profiles of whole blood in lung adenocarcinoma. PLoS ONE. 2012;7(9):e46054.

62. Li G, Pu Y. MicroRNA signatures in total peripheral blood of gallbladder cancer patients. Tumour Biol. 2015;36(9):6985–90.

63. Yu KH, Lo YM, Tse GM, Chan KC, Chan AB, Chow KC, Ma TK, Vlantis AC, Leung SF, van Hasselt CA, et al. Quantitative analysis of cell-free Epstein-Barr virus (EBV)-encoded small RNAs (EBERs) associated with poor prognosis of head and neck carcinomas. Oncotarget. 2017;8(16):27328–38.

64. Yu KH, Lo YM, Tse GM, Chan KC, Chan AB, Chow KC, Ma TK, Vlantis AC, Leung SF, van Hasselt CA, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nonnasopharyngeal head and neck carcinomas. Clin Cancer Res. 2004;10(5):1726–32.

65. Xia X, Li Y, Wang W, Tang F, Tan J, Sun L, Li Q, Sun L, Tang B, He S. MicroRNA-1908 functions as a glioblastoma oncogene by suppressing PTEN tumor suppressor pathway. Mol Cancer. 2015;14:154.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.